Published studies reporting the frequency of venous thromboembolism (VTE) in statin users and non-users.
| Study . | Type . | No. of participants . | Drug . | Result . |
|---|---|---|---|---|
| Hazard ratios (HR), odds ratios (OR), and incidence rate ratio (IRR) with 95% confidence intervals for comparisons of VTE prevalence in statin users versus non-users*, and statin use or non-use in persons with or without VTE**. | ||||
| +VTE events/100 person-years. | ||||
| RCT indicates randomized controlled trial; HERS, Heart and Estrogen/Progestin Replacement Study. | ||||
| Glynn 20094 | RCT (secondary outcome) | 8901/8901* | Rosuvastatin | HR 0.57 (0.37–0.86) + |
| Ramcharan 20095 | Case-control | 4538/5914** | Any statin | OR 0.55 (0.46–0.67) |
| Sorensen 20096 | Case-control | 5824/58240** | Any statin | OR 0.74 (0.63–0.85) |
| Smeeth 20098 | Cohort study | 129,288/600,241* | Any statin | HR no statin vs. statin 1.18 (1.06–1.31) |
| Lacut 20049 | Case-control | 377/377** | Any statin | OR 0.42 (0.23–0.76) |
| Herrington 200210 | Nonrandomized comparison (part of HERS) | 1712/1051* | Any statin | HR 0.40 (0.18–0.91) |
| Yang 200211 | Retrospective cohort study | 22,993/61,100* | Any statin | IRR current/recent statin use 0.8 (0.3–2.7) |
| Ray 200112 | Retrospective cohort study | 77,993/47,869* | Any statin | HR 0.78 (0.69–0.87) |
| Study . | Type . | No. of participants . | Drug . | Result . |
|---|---|---|---|---|
| Hazard ratios (HR), odds ratios (OR), and incidence rate ratio (IRR) with 95% confidence intervals for comparisons of VTE prevalence in statin users versus non-users*, and statin use or non-use in persons with or without VTE**. | ||||
| +VTE events/100 person-years. | ||||
| RCT indicates randomized controlled trial; HERS, Heart and Estrogen/Progestin Replacement Study. | ||||
| Glynn 20094 | RCT (secondary outcome) | 8901/8901* | Rosuvastatin | HR 0.57 (0.37–0.86) + |
| Ramcharan 20095 | Case-control | 4538/5914** | Any statin | OR 0.55 (0.46–0.67) |
| Sorensen 20096 | Case-control | 5824/58240** | Any statin | OR 0.74 (0.63–0.85) |
| Smeeth 20098 | Cohort study | 129,288/600,241* | Any statin | HR no statin vs. statin 1.18 (1.06–1.31) |
| Lacut 20049 | Case-control | 377/377** | Any statin | OR 0.42 (0.23–0.76) |
| Herrington 200210 | Nonrandomized comparison (part of HERS) | 1712/1051* | Any statin | HR 0.40 (0.18–0.91) |
| Yang 200211 | Retrospective cohort study | 22,993/61,100* | Any statin | IRR current/recent statin use 0.8 (0.3–2.7) |
| Ray 200112 | Retrospective cohort study | 77,993/47,869* | Any statin | HR 0.78 (0.69–0.87) |